Zoox Recalls 332 Robotaxis for 'Human-Like' Driving Flaws Like Crossing Center Lines
Amazon's autonomous vehicle unit, Zoox, has recalled software on 332 robotaxis for making 'human-like' errors such as crossing center lines and blocking crosswalks. We analyze the recall's deeper implications.
What if driving like a human is no longer good enough? Amazon's self-driving unit, Zoox, has recalled its robotaxi software precisely because its AI was making maneuvers that are common for human drivers. According to documents filed with the National Highway Traffic Safety Administration (NHTSA), the company issued a voluntary recall for 332 vehicles over concerns its autonomous system caused them to cross over the center line or block crosswalks.
While there haven't been any collisions associated with the issue, Zoox noted in the NHTSA filing that it could increase the risk of a crash. The company currently provides free, driverless rides to the public in parts of San Francisco and Las Vegas.
The 'Human Driver' Dilemma
A Zoox spokesperson told TechCrunch the company identified maneuvers that, "while common for human drivers, didn’t meet its standards." For instance, a robotaxi might stop in a crosswalk to avoid blocking an intersection at a red light. In other cases, the vehicle made a late turn, resulting in a wide turn that crossed into the opposing lane.
The issue was first flagged on August 26 when a Zoox vehicle made a wide right turn and partially entered the oncoming lane. After monitoring its data, Zoox identified 62 similar instances between August 26 and December 5.
A Pattern of Software Fixes
Zoox said in a statement it has "successfully identified and deployed targeted software improvements to address the root causes." Updates were rolled out on November 7 and again in mid-December. The recall affects vehicles that were operating on public roads between March 13 and December 18.
This isn't the first software stumble for Zoox this year. The company issued a recall in March for unexpected hard braking and two more in May to address concerns about the system’s ability to predict the movement of other road users.
본 콘텐츠는 AI가 원문 기사를 기반으로 요약 및 분석한 것입니다. 정확성을 위해 노력하지만 오류가 있을 수 있으며, 원문 확인을 권장합니다.
관련 기사
바이오마린이 혈우병 A 유전자 치료제 '록타비안'의 미국 FDA 재심사 신청 및 유럽 EMA의 긍정적 의견 확보 소식을 전했습니다. 2026년 미국과 유럽 시장 동시 진출 가능성이 열렸습니다.
알파벳의 자회사 웨이모가 샌프란시스코 정전 사태로 자율주행 차량이 마비된 후 긴급 소프트웨어 업데이트를 발표했다. 이번 사태의 의미와 자율주행 기술의 과제를 분석한다.
알파벳의 웨이모가 샌프란시스코 대규모 정전 사태로 로보택시 운행을 중단한 후, 차량 소프트웨어 업데이트와 비상 대응 프로토콜 개선 등 3가지 대책을 발표했다.
미 국방부 연례 보고서는 중국이 2027년 대만 침공 시나리오에 맞춰 미래 전쟁의 판도를 바꿀 양자 기술 개발에 총력을 기울이고 있다고 경고했다. 이는 미중 기술 패권 경쟁의 새로운 국면을 예고한다.